Investigation of Autonomic Dysfunction in Patients With Familial Mediterranean Fever

NCT ID: NCT05596643

Last Updated: 2022-10-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

60 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-03-15

Study Completion Date

2022-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Familial Mediterranean Fever (FMF) is the most common inherited autoinflammatory disease affecting 150,000 patients worldwide. Periodic febrile exacerbations, peritonitis, and pleuritis are characteristic disease features. Dysregulation of IL-1β secretion has an important role in the pathophysiology of the disease, and IL-1β also serves as a therapeutic target. Chronic inflammation has been associated with early atherosclerotic and cardiovascular disease in various rheumatic diseases. An increased risk for cardiovascular events associated with disease activity has been described in rheumatoid arthritis, psoriatic arthritis, and systemic lupus erythematosus. In addition, autonomic nervous system dysfunction may contribute to increased cardiovascular risk in patients with inflammatory disease. For example, decreased heart rate variability is an important feature of cardiac autonomic dysfunction and is an isolated risk factor for cardiovascular events. Autonomic dysfunction studies related to FMF have conflicting results.

The aim of this study was to determine autonomic dysfunction symptoms and objective findings in patients with FMF; Demographic characteristics, disease characteristics, inflammatory burden, fatigue level, sleep quality, presence of fibromyalgia and their relationship with quality of life were evaluated and compared with healthy controls.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Familial Mediterranean Fever Autonomic Dysfunction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients diagnosed with Familial Mediterranean Fever

Composite Autonomic Symptom Score-31

Intervention Type DIAGNOSTIC_TEST

Standardized questionnaire to determine the level of autonomic dysfunction

r-r interval variability with normal breathing

Intervention Type DIAGNOSTIC_TEST

electrophysiological test to detect parasympathetic dysfunction

r-r interval variability with deep breathing

Intervention Type DIAGNOSTIC_TEST

electrophysiological test to detect parasympathetic dysfunction

Valsalva ratio

Intervention Type DIAGNOSTIC_TEST

electrophysiological test to detect parasympathetic dysfunction

30:15 ratio

Intervention Type DIAGNOSTIC_TEST

electrophysiological test to detect parasympathetic dysfunction

sympathetic skin response

Intervention Type DIAGNOSTIC_TEST

electrophysiological test to detect sympathetic dysfunction

blood pressure response to standing

Intervention Type DIAGNOSTIC_TEST

clinical test to detect sympathetic dysfunction

blood pressure response to sustained handgrip test

Intervention Type DIAGNOSTIC_TEST

clinical test to detect sympathetic dysfunction

Hospital anxiety and depression scale

Intervention Type OTHER

Standardized questionnaire to investigate the depression and anxiety

Fibromyalgia rapid screening tool

Intervention Type DIAGNOSTIC_TEST

Standardized questionnaire to determine the presence of fibromyalgia

Familial Mediterranean Fever Quality of life scale

Intervention Type OTHER

Standardized questionnaire to investigate the quality of life in Familial Mediterranean Fever patients

Jenkins Sleep Evaluation Scale

Intervention Type OTHER

Standardized questionnaire to investigate the sleep quality and disturbance

The Fatigue Severity Scale

Intervention Type OTHER

Standardized questionnaire to investigate the fatigue severity

Healthy Controls

Composite Autonomic Symptom Score-31

Intervention Type DIAGNOSTIC_TEST

Standardized questionnaire to determine the level of autonomic dysfunction

r-r interval variability with normal breathing

Intervention Type DIAGNOSTIC_TEST

electrophysiological test to detect parasympathetic dysfunction

r-r interval variability with deep breathing

Intervention Type DIAGNOSTIC_TEST

electrophysiological test to detect parasympathetic dysfunction

Valsalva ratio

Intervention Type DIAGNOSTIC_TEST

electrophysiological test to detect parasympathetic dysfunction

30:15 ratio

Intervention Type DIAGNOSTIC_TEST

electrophysiological test to detect parasympathetic dysfunction

sympathetic skin response

Intervention Type DIAGNOSTIC_TEST

electrophysiological test to detect sympathetic dysfunction

blood pressure response to standing

Intervention Type DIAGNOSTIC_TEST

clinical test to detect sympathetic dysfunction

blood pressure response to sustained handgrip test

Intervention Type DIAGNOSTIC_TEST

clinical test to detect sympathetic dysfunction

Hospital anxiety and depression scale

Intervention Type OTHER

Standardized questionnaire to investigate the depression and anxiety

Fibromyalgia rapid screening tool

Intervention Type DIAGNOSTIC_TEST

Standardized questionnaire to determine the presence of fibromyalgia

Jenkins Sleep Evaluation Scale

Intervention Type OTHER

Standardized questionnaire to investigate the sleep quality and disturbance

The Fatigue Severity Scale

Intervention Type OTHER

Standardized questionnaire to investigate the fatigue severity

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Composite Autonomic Symptom Score-31

Standardized questionnaire to determine the level of autonomic dysfunction

Intervention Type DIAGNOSTIC_TEST

r-r interval variability with normal breathing

electrophysiological test to detect parasympathetic dysfunction

Intervention Type DIAGNOSTIC_TEST

r-r interval variability with deep breathing

electrophysiological test to detect parasympathetic dysfunction

Intervention Type DIAGNOSTIC_TEST

Valsalva ratio

electrophysiological test to detect parasympathetic dysfunction

Intervention Type DIAGNOSTIC_TEST

30:15 ratio

electrophysiological test to detect parasympathetic dysfunction

Intervention Type DIAGNOSTIC_TEST

sympathetic skin response

electrophysiological test to detect sympathetic dysfunction

Intervention Type DIAGNOSTIC_TEST

blood pressure response to standing

clinical test to detect sympathetic dysfunction

Intervention Type DIAGNOSTIC_TEST

blood pressure response to sustained handgrip test

clinical test to detect sympathetic dysfunction

Intervention Type DIAGNOSTIC_TEST

Hospital anxiety and depression scale

Standardized questionnaire to investigate the depression and anxiety

Intervention Type OTHER

Fibromyalgia rapid screening tool

Standardized questionnaire to determine the presence of fibromyalgia

Intervention Type DIAGNOSTIC_TEST

Familial Mediterranean Fever Quality of life scale

Standardized questionnaire to investigate the quality of life in Familial Mediterranean Fever patients

Intervention Type OTHER

Jenkins Sleep Evaluation Scale

Standardized questionnaire to investigate the sleep quality and disturbance

Intervention Type OTHER

The Fatigue Severity Scale

Standardized questionnaire to investigate the fatigue severity

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

COMPASS-31 SSR HADS FIRST FMFQoL FSS

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Familial Mediterranean Fever group;

1. Being between the ages of 18-65
2. Having a definite diagnosis of Familial Mediterranean Fever according to Livneh criteria

Healthy control group;

1. Being between the ages of 18-65
2. Absence of any disease diagnosis

Exclusion Criteria

1. Liver or kidney failure
2. Pregnancy
3. Diabetes mellitus
4. Thyroid diseases
5. Those who use neuroprotective or antihypertensive drugs
6. Vitamin B12 deficiency
7. Anemia
8. Paraneoplastic neuropathy
9. Alcoholism
10. Cardiac failure
11. Cardiac arrhythmia
12. Acute thrombosis
13. Having a diagnosis of another systemic rheumatic disease
14. Persons who did not give consent to participate in the study
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Marmara University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Mehmet Tuncay Duruöz, Prof

Role: PRINCIPAL_INVESTIGATOR

Marmara University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Marmara University School of Medicine, Pendik Education and Research Hospital, Department of Physical Medicine and Rehabilitation

Istanbul, , Turkey (Türkiye)

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

İmran Kalkan

Role: CONTACT

+90 530 340 5594

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

İmran Kalkan

Role: primary

+90 530 340 5594

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

09.2021.1427

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.